You are on the International Aridol Site. US residents select United States.
The mannitol challenge test (Aridol®/Osmohale®) is an indirect osmotic bronchial challenge test that can be used to identify bronchial hyperresponsivesness, a key clinical feature of respiratory conditions such as asthma.
Aridol/Osmohale is manufactured by Pharmaxis Ltd (Frenchs Forest, Sydney Australia) and is available as a standardised test kit containing pre-filled mannitol capsules and a hand held dry powder inhaler.
During a mannitol challenge test, the subject inhales increasing doses of mannitol with their lung function (Forced Expiratory Volume in one second- FEV1) measured after each dose to determine the level of bronchial hyperresponsiveness.
For more detailed product information, test instructions, approval status and distributor details in your country please refer to the country specific homepages by clicking on Product Information from the menu, or the world map.
This website is designed as a resource for healthcare professionals with an interest in bronchial challenge testing and is not intended to replace the advice of a qualified health professional.
The mannitol challenge test should only be performed by a suitably trained healthcare professional. Please refer to the approved product information or summary of product characteristics for your country prior to performing this challenge test.
Inhaled mannitol (Bronchitol ®) has been developed as a therapeutic agent designed to hydrate the airway surface of the lungs, improve lung hygiene and promote mucus clearance in the lungs of patients with cystic fibrosis. For further information about the clinical development of mannitol as a therapeutic please refer to the Pharmaxis website www.pharmaxis.com.au
Select your country from the drop down below to access approved product, testing and supply information specific to your country
Manufactured by Pharmaxis Ltd
20 Rodborough Road
Frenchs Forest NSW 2086
Aridol is a registered trademark of Pharmaxis Ltd.